Trial CTSU-9177

Phase II Study of Dose-Adjusted EPOCH +/- Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma.

Type: Cancer Therapy
Phase: Phase II
Status: Open to Accrual
Treatments: Immunomodulator, Immunotherapy
Randomized: No
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Anil Tulpule, M.D.
Other Trial Staff: Christine Duran, D.M., Teh-Chun Wang, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.